arGEN-X strong outperformer in European biotech sector

Because her big gain of 37 percent since early this year, the share is one of the better shares in the sector.

Momentum biotech sector

The sector trades now at 52 times the earnings per share. The sector trades at -12,98 times the book value per share. Since 2012 the sector is 193 percent higher and since 2007 268 percent higher.

For this year arGEN-X's revenue will be around 75,23 million euros. This is according to the average of the analysts' estimates. This is slightly more than 2018's revenue of 69,78 million euros.

Historical revenues and results arGEN-X plus estimates 2020

The analysts expect for 2020 a net loss of 279 million euros. According to most of the analysts the company will have a loss per share for this book year of 6,79 euros. So the price/earnings-ratio equals -29,06.

Analysts don't expect the company to pay a dividend. The average dividend yield of the biotech companies equals a limited 1,16 percent.

Recent target prices around 202 euros

The most recent recommendations for the biotech company are from Goldman Sachs, KBC Securities and DeGroof Petercam.

arGEN-X's market capitalization is based on the number of outstanding shares around 7,1 billion euros. The arGEN-X stock was the past 12 months quite volatile. Since last June the stock is even 81 percent higher. This year the stock price moved between 93 and 215 euro.

Historical stock prices arGEN-X2007-2020

Click here for dividend arGEN-X. At 11.56 the stock trades 0 percent lower at 197,3 euros.

Analist.nl Nieuwsdienst: +31 084-0032-842
nieuws@analist.nl

Copyright analist.nl B.V.
All rights reserved. Any redistribution, duplication or archiving prohibited. Analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.